Review
doi: 10.1517/14712590903379502.
Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines
Affiliations
- PMID: 20088713
- DOI: 10.1517/14712590903379502
Item in Clipboard
Review
Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines
Expert Opin Biol Ther.
2010 Feb.
Abstract
Coxsackievirus strain CVB3 is widespread in the human population and causes myocarditis or pancreatitis. However, despite its clinical impact, there is no commercially available and clinically applicable prophylactic vaccine. This study examines the characteristics of attenuated CVB3 strains developed so far and their application as live-attenuated CVB3 vaccines, and discusses problems to be overcome in the development of live-attenuated vaccines.
Similar articles
-
Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis.Vaccine. 2009 Mar 18;27(13):1974-83. doi: 10.1016/j.vaccine.2009.01.008. Epub 2009 Jan 23. Vaccine. 2009. PMID: 19168108
-
Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.Expert Rev Vaccines. 2008 Dec;7(10):1557-67. doi: 10.1586/14760584.7.10.1557. Expert Rev Vaccines. 2008. PMID: 19053211 Review.
-
Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection.Vaccine. 2004 Sep 9;22(27-28):3603-12. doi: 10.1016/j.vaccine.2004.03.033. Vaccine. 2004. PMID: 15315839
-
Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain.Am J Pathol. 1997 Jun;150(6):2197-207. Am J Pathol. 1997. PMID: 9176409 Free PMC article.
-
Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.Int J Med Microbiol. 2008 Jan;298(1-2):127-34. doi: 10.1016/j.ijmm.2007.08.010. Epub 2007 Sep 25. Int J Med Microbiol. 2008. PMID: 17897883 Review.
Cited by
-
Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges.Viruses. 2021 Jun 5;13(6):1082. doi: 10.3390/v13061082. Viruses. 2021. PMID: 34198859 Free PMC article.
-
Is a multivalent hand, foot, and mouth disease vaccine feasible?Hum Vaccin Immunother. 2015;11(11):2688-704. doi: 10.1080/21645515.2015.1049780. Epub 2015 May 26. Hum Vaccin Immunother. 2015. PMID: 26009802 Free PMC article. Review.
-
In vitro molecular characterization of RNA-proteins interactions during initiation of translation of a wild-type and a mutant Coxsackievirus B3 RNAs.Mol Biotechnol. 2013 Jun;54(2):515-27. doi: 10.1007/s12033-012-9592-x. Mol Biotechnol. 2013. PMID: 22923320
-
EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.Emerg Microbes Infect. 2016 Jul 20;5(7):e75. doi: 10.1038/emi.2016.73. Emerg Microbes Infect. 2016. PMID: 27436364 Free PMC article. Review.
-
Role of RNA structure motifs in IRES-dependent translation initiation of the coxsackievirus B3: new insights for developing live-attenuated strains for vaccines and gene therapy.Mol Biotechnol. 2013 Oct;55(2):179-202. doi: 10.1007/s12033-013-9674-4. Mol Biotechnol. 2013. PMID: 23881360 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
